Latest Mental Health News

Page 1 of 6
InhaleRx Limited has successfully closed its entitlement offer and placement, raising $857,730 to support the clinical development of inhaled treatments targeting cancer pain and mental health conditions.
Ada Torres
Ada Torres
23 Dec 2025
TrivarX Limited has reported compelling clinical trial results demonstrating its single-lead ECG algorithm’s high sensitivity in detecting major depressive episodes among US veterans, marking a significant step in objective mental health screening.
Ada Torres
Ada Torres
18 Dec 2025
Emyria has secured its first Empax clinic in Victoria, marking a significant step in its multi-state expansion and validating its scalable, reimbursed national mental health platform.
Ada Torres
Ada Torres
16 Dec 2025
Emyria Limited is scaling up its Perth Empax clinic with increased therapist approvals and treatment rooms, setting the stage for broader national clinical growth next year.
Ada Torres
Ada Torres
11 Dec 2025
InhaleRx advances its clinical pipeline with a new oral treatment for resistant depression and plans a strategic rebrand to Nexalis Therapeutics, signaling a broader focus beyond inhaled therapies.
Ada Torres
Ada Torres
10 Dec 2025
InhaleRx Limited has secured $427,500 from an initial tranche of its $1 million capital raise, issuing 17.1 million shares to support its inhaled therapies targeting pain and mental health conditions.
Ada Torres
Ada Torres
9 Dec 2025
InhaleRx Limited has introduced SRX-25, an oral fixed-dose combination therapy targeting Treatment-Resistant Depression, aiming to improve patient access and adherence. The company also secured $1 million in capital to advance clinical development and plans a strategic rebrand.
Ada Torres
Ada Torres
26 Nov 2025
Emyria Limited is fast-tracking its national rollout of Empax mental health clinics, backed by a strong $8 million institutional placement and new dual-payer funding pathways.
Ada Torres
Ada Torres
20 Nov 2025
Tryptamine Therapeutics has enrolled its second patient in a pioneering clinical trial using IV-infused psilocin to treat Binge Eating Disorder, with first dosing scheduled for December and results expected early next year.
Ada Torres
Ada Torres
18 Nov 2025
Orica Limited reported a 6% increase in revenue to AUD 8.14 billion and a 23% rise in EBIT to AUD 992.2 million for FY2025, alongside record safety performance and significant strides in decarbonisation.
Maxwell Dee
Maxwell Dee
13 Nov 2025
TrivarX Limited has exercised its option to acquire the innovative Stabl-Im brain imaging technology, aiming to revolutionize early detection of brain tumours pending shareholder approval.
Ada Torres
Ada Torres
5 Nov 2025
Tryptamine Therapeutics has initiated the world’s first clinical trial of its IV-infused psilocin drug, TRP-8803, targeting Binge Eating Disorder, alongside a pioneering EEG biomarker collaboration and new funding.
Ada Torres
Ada Torres
31 Oct 2025